Rare disease is a word used to describe pathological disorders that have a very low incidence and prevalence. According to the "Rare Condition Act," passed in the United States in 2002, a disease must affect fewer than 200,000 Americans and have a prevalence equal to or less than 1 in 1,500 people to be classified as rare. The skeletal system, on the other hand, may be impacted by rare disorders of unknown aetiology for which no genetic aetiology has been identified, only a genetic predisposition. The musculoskeletal system is affected by orthopaedic injuries and disorders. Muscles, bones, nerves, joints, ligaments, tendons, and other connective tissues are all part of this bodily system. Chronic orthopaedic conditions or an injury might cause damage to any of these tissues or structures. Variations in genes that control skeletal development and regulation are responsible for several uncommon disorders affecting the musculoskeletal system. Understanding the genetic foundation and phenotypic connections, depending on the type and position within the same gene, has been made possible by recent developments in molecular genetics. Almost 400 different types of skeletal dysplasias have been identified so far.
Title : Revolutionizing orthopedics: The future of biomechanics through artificial intelligence
Moataz Eltoukhy, University of Miami, United States
Title : The effect of OTC N-acetyl-cysteine on cobaltemia and cobalturia from cobalt-chromium orthopedic implants
Stephen S Tower, University of Alaska Anchorage, United States
Title : A data driven approach to prehabilitation and rehabilitation for hip and knee replacement patients
Diana Hodgins, Dynamic Metrics Ltd, United Kingdom
Title : Long-term results from the use of a pre-fabricated articulating antibiotic-loaded cement spacer (Spacer G) in two-stage revisions for infected total hip replacements
Muhammad Yusuf, East Lancashire Hospitals NHS Trust, United Kingdom
Title : Platelet-Rich Plasma (PRP) as a therapeutic approach for joint osteoarthritis: A focus on regenerative potential and quality control in clinical trials
Hany Abu Farsakh, Al Istishari Hospital, Jordan
Title : Efficacy of bone healing stimulator (Exogen) on fracture non-union: A single centre experience
Muhammad Yusuf, East Lancashire Hospitals NHS Trust, United Kingdom